Blood transfusion therapy for β-thalassemia major and hemoglobin E β-thalassemia: adequacy, trends, and determinants in Sri Lanka.
dc.contributor.author | Mettananda, S. | |
dc.contributor.author | Pathiraja, H. | |
dc.contributor.author | Peiris, R. | |
dc.contributor.author | Wickramarathne, N. | |
dc.contributor.author | Bandara, D. | |
dc.contributor.author | de Silva, U. | |
dc.contributor.author | Mettananda, C. | |
dc.contributor.author | Premawardhena, A. | |
dc.date.accessioned | 2019-02-21T07:04:29Z | |
dc.date.available | 2019-02-21T07:04:29Z | |
dc.date.issued | 2019 | |
dc.description | Indexed in Medline | en_US |
dc.description.abstract | BACKGROUND: Regular blood transfusion therapy still remains the cornerstone in the management of β-thalassemia. Although recommendations are clear for patients with β-thalassemia major, uniform transfusion guidelines are lacking for patients with hemoglobin E β-thalassemia. In this study, we aim to describe the adequacy, trends, and determinants of blood transfusion therapy in a large cohort of pediatric patients with β-thalassemia major and hemoglobin E β-thalassemia. METHODS/PROCEDURE: This cross-sectional study was performed among all regularly transfused patents with β-thalassemia aged 2 to 18 years attending three large thalassemia centers in Sri Lanka. Data were collected using an interviewer-administered questionnaire, perusal of clinical records, and physical examination of patients by trained doctors. RESULTS: A total of 328 patients (male 47%) were recruited; 83% had β-thalassemia major, whereas 16% had hemoglobin E β-thalassemia. Sixty-one percent of patients had low pretransfusion hemoglobin levels (< 9.0 g/dL) despite receiving high transfusion volumes (> 200 mL/kg/year) by a majority (56%). Median pretransfusion hemoglobin was significantly lower in patients with hemoglobin E β-thalassemia compared with β-thalassemia major (P < 0.001); however, there was no difference in requirement for high transfusion volumes over 200 mL/kg/year in both groups (P = 0.14). Hepatomegaly and splenomegaly were more common in hemoglobin E β-thalassemia and were associated with lower pretransfusion hemoglobin. Transfusion requirements were higher among patients with hepatitis C and in those who are underweight. CONCLUSIONS: Over 60% of regularly transfused patients with β-thalassemia have low pretransfusion hemoglobin levels despite receiving large transfusion volumes. Patients with hemoglobin E β-thalassemia are undertransfused and specific recommendations should be developed to guide transfusions in these patients. | en_US |
dc.identifier.citation | Pediatric Blood and Cancer.2019: e27643 | en_US |
dc.identifier.issn | 1545-5009 (Print) | |
dc.identifier.issn | 1545-5017 (Electronic) | |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/19972 | |
dc.language.iso | en | en_US |
dc.publisher | John Wiley | en_US |
dc.subject | Hemoglobinopathies | en_US |
dc.title | Blood transfusion therapy for β-thalassemia major and hemoglobin E β-thalassemia: adequacy, trends, and determinants in Sri Lanka. | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- Mettananda_et_al-2019-Pediatric_Blood_&_Cancer.pdf
- Size:
- 417.91 KB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 52 B
- Format:
- Item-specific license agreed upon to submission
- Description: